MedTrace Logo

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

NCT01082198 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2013-08-26

No results posted yet for this study

Summary

RATIONALE: Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best way to give melanoma vaccine in treating patients with stage III melanoma after surgery to remove the lymph nodes.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine

BIOLOGICAL

HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine

BIOLOGICAL

autologous melanoma lysate-pulsed autologous dendritic cell vaccine

BIOLOGICAL

autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine

BIOLOGICAL

dendritic cell-idiotype-keyhole limpet hemocyanin vaccine

OTHER

flow cytometry

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • Maria Sklodowska-Curie National Research Institute of Oncology

    lead OTHER

Principal Investigators

  • Sergiusz Markowicz, MD · Maria Sklodowska-Curie National Research Institute of Oncology

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2010-04-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082198 on ClinicalTrials.gov